Compare ACR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACR | ACOG |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4M | 110.4M |
| IPO Year | N/A | N/A |
| Metric | ACR | ACOG |
|---|---|---|
| Price | $19.01 | $6.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $24.50 | $18.00 |
| AVG Volume (30 Days) | 16.0K | ★ 53.1K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $146.05 |
| Revenue Next Year | N/A | $127.74 |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.51 | $3.75 |
| 52 Week High | $24.61 | $10.88 |
| Indicator | ACR | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 65.38 |
| Support Level | $18.73 | $5.00 |
| Resistance Level | $18.98 | $6.59 |
| Average True Range (ATR) | 0.39 | 0.46 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 20.60 | 96.84 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.